OR WAIT null SECS
March 20, 2023
Europe trade and lobby group says implementation issues related to the legislation could impact 420 trials—and 42,200 patients—over the next three years.
Webinar Date/Time: Session 1: Tuesday, April 18th, 2023 at 8am EDT | 1pm BST | 2pm CEST Session 2: Tuesday, April 18th, 2023 at 2pm EDT | 11am PDT | 7pm BST
March 07, 2023
Webinar Date/Time: Wednesday, March 29th, 2023 at 11am | 8am PDT | 4pm BST | 5pm CEST
March 03, 2023
The key issues for industry and FDA as the Orphan Drug Act hits its 40th anniversary.
March 02, 2023
Reformed EMA looks to tackle challenges in drug development, pediatric medicines, and unmet medical need.
February 27, 2023
The Association of the British Pharmaceutical Industry greets the development with mix of relief and urgency.
February 23, 2023
Report by the Government Accountability Office calls for ramped-up oversight by FDA of institutional review boards.
February 20, 2023
Pandemic and supply shortage among factors in slow transition to new rules.
February 15, 2023
Probe targets agency’s role in advising on drug testing and submissions.
February 13, 2023
EMA opens public discussion on envisioned platform to encourage multi-stakeholder interactions and shared understanding.